tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hyperlipidemias D006949 73 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Hypersensitivity D006967 22 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Hypertension D006973 115 associated lipids
Hypertension, Portal D006975 12 associated lipids
Hypertension, Renal D006977 9 associated lipids
Hypoglycemia D007003 13 associated lipids
Hypotension D007022 41 associated lipids
Hypothermia D007035 19 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Immune System Diseases D007154 3 associated lipids
Impetigo D007169 3 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Infection D007239 6 associated lipids
Inflammation D007249 119 associated lipids
Influenza, Human D007251 11 associated lipids
Insulin Resistance D007333 99 associated lipids
Intertrigo D007402 1 associated lipids
Intestinal Atresia D007409 3 associated lipids
Intestinal Fistula D007412 1 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Intussusception D007443 1 associated lipids
Ischemia D007511 18 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Keloid D007627 12 associated lipids
Kidney Diseases D007674 29 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Labyrinthitis D007762 2 associated lipids
Leg Injuries D007869 2 associated lipids
Legionellosis D007876 3 associated lipids
Lentigo D007911 1 associated lipids
Leukemia D007938 74 associated lipids
Leukemia P388 D007941 43 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Leukocytosis D007964 9 associated lipids
Leukoplakia D007971 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Lichen Planus D008010 3 associated lipids
Listeriosis D008088 12 associated lipids
Liver Abscess D008100 6 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gold BG FK506 and the role of the immunophilin FKBP-52 in nerve regeneration. 1999 Drug Metab. Rev. pmid:10461545
Morris-Stiff GJ et al. Conversion from cyclosporin (Neoral) to tacrolimus (Prograf) in renal allograft recipients with chronic graft nephropathy: results of an observational study. 1999 Transpl. Int. pmid:10460877
Burke GA et al. The role of early renal biopsy in cyclosporin induced thrombotic microangiopathy. 1999 Pediatr. Nephrol. pmid:10460501
Drachenberg CB et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. 1999 Transplantation pmid:10459544
Van Gelder RN and Kaplan HJ Immunosuppression in uveitis therapy. 1999 Springer Semin. Immunopathol. pmid:10457590
Hachida M et al. Combined use of deoxyspergualin and FK 506 for temporary circulatory assist. 1999 Transplant. Proc. pmid:10455968
Kobashigawa JA Postoperative management following heart transplantation. 1999 Transplant. Proc. pmid:10455966
Jiang H and Kobayashi M Differences between cyclosporin A and tacrolimus in organ transplantation. 1999 Transplant. Proc. pmid:10455942
Miura S et al. The beneficial effects of FK 506 on living-related renal transplantation in presensitized recipients. 1999 Transplant. Proc. pmid:10455940
Jones JW et al. Long-term survival of an extremity composite tissue allograft with FK506-mycophenolate mofetil therapy. 1999 Surgery pmid:10455910
Penson MG et al. Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. 1999 J. Heart Lung Transplant. pmid:10452348
Armstrong HM et al. Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicity. 1999 Bioorg. Med. Chem. Lett. pmid:10450987
Goulet MT et al. C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study. 1999 Bioorg. Med. Chem. Lett. pmid:10450986
Volbracht C et al. ATP controls neuronal apoptosis triggered by microtubule breakdown or potassium deprivation. 1999 Mol. Med. pmid:10449809
Uchiyama H et al. Approach to withdrawal from tacrolimus in a fully allogeneic murine skin graft model. 1999 Immunology pmid:10447745
Kur F et al. Tacrolimus (FK506) as primary immunosuppressant after lung transplantation. 1999 Thorac Cardiovasc Surg pmid:10443520
Magee CC et al. Nocardial infection in a renal transplant recipient on tacrolimus and mycophenolate mofetil. 1999 Clin. Nephrol. pmid:10442495
Moxey-Mims MM Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) 1999 Transplantation pmid:10440413
Sheikh AM et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. 1999 Transplantation pmid:10440408
Tsuji Y et al. Effects of cyclosporin A, FK506 and steroid hormones on hair growth. 1999 Exp. Dermatol. pmid:10439282
Harikrishnan P and Harden PN Tacrolimus can resolve cyclosporin-induced gingival hyperplasia. 1999 Nephrol. Dial. Transplant. pmid:10435907
Briggs WA et al. Lymphocyte suppression by rolipram with other immunosuppressive drugs. 1999 J Clin Pharmacol pmid:10434230
Shinkura N et al. Autoantibodies to FK506 binding protein 12 (FKBP12) in autoimmune diseases. 1999 Autoimmunity pmid:10433096
Pollock R and Rivera VM Regulation of gene expression with synthetic dimerizers. 1999 Meth. Enzymol. pmid:10432459
Levy GA Neoral/cyclosporine-based immunosuppression. 1999 Liver Transpl Surg pmid:10431016
Soccal PM et al. Improvement of drug-induced chronic renal failure in lung transplantation. 1999 Transplantation pmid:10428288
Reichenspurner H et al. Optimization of the immunosuppressive protocol after lung transplantation. 1999 Transplantation pmid:10428269
Kahan BD An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. 1999 Transplantation pmid:10428260
Jamieson NV Adult small intestinal transplantation in Europe. 1999 Apr-Jun Acta Gastroenterol. Belg. pmid:10427790
Pirenne J Contribution of large animal models to the development of clinical intestinal transplantation. 1999 Apr-Jun Acta Gastroenterol. Belg. pmid:10427786
Kato K et al. Modulation of long-term potentiation induction in the hippocampus by N-methyl-D-aspartate-mediated presynaptic inhibition. 1999 Neuroscience pmid:10426482
Becker JW et al. 32-Indolyl ether derivatives of ascomycin: three-dimensional structures of complexes with FK506-binding protein. 1999 J. Med. Chem. pmid:10425089
Dunn SE et al. Calcineurin is required for skeletal muscle hypertrophy. 1999 J. Biol. Chem. pmid:10419511
Dalvit C et al. Use of organic solvents and small molecules for locating binding sites on proteins in solutions. 1999 J. Biomol. NMR pmid:10419292
Remitz A et al. Tacrolimus ointment improves psoriasis in a microplaque assay. 1999 Br. J. Dermatol. pmid:10417522
Mrowietz U Macrolide immunosuppressants. 1999 Jul-Aug Eur J Dermatol pmid:10417434
Min DI et al. Sudden hearing loss associated with tacrolimus in a kidney-pancreas allograft recipient. 1999 Pharmacotherapy pmid:10417040
Finn WF FK506 nephrotoxicity. 1999 May-Jul Ren Fail pmid:10416209
Kuroda S et al. The immunosuppressants cyclosporin A and FK506 equally ameliorate brain damage due to 30-min middle cerebral artery occlusion in hyperglycemic rats. 1999 Brain Res. pmid:10415369
Bavetta S et al. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: neuroprotection and local regeneration. 1999 Exp. Neurol. pmid:10415144
Przepiorka D et al. Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation. 1999 Bone Marrow Transplant. pmid:10414918
Varghese Z et al. Calcineurin inhibitors enhance low-density lipoprotein oxidation in transplant patients. 1999 Kidney Int. Suppl. pmid:10412758
Muegge I et al. Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. 1999 J. Med. Chem. pmid:10411471
Rhew JH et al. Induction of fibronectin gene expression by inhibitors of protein phosphatase type 2B in normal and transformed fibroblasts. 1999 Exp. Mol. Med. pmid:10410305
Hebert MF and Lam AY Diltiazem increases tacrolimus concentrations. 1999 Ann Pharmacother pmid:10410178
Kaibori M et al. Immunosuppressant FK506 inhibits inducible nitric oxide synthase gene expression at a step of NF-kappaB activation in rat hepatocytes. 1999 J. Hepatol. pmid:10406194
Banerjee C et al. Ca2+ and calmodulin-dependent protein phosphatase from Leishmania donovani. 1999 Parasitology pmid:10406035
Timmermann W et al. Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. 1999 Transplantation pmid:10401762
Tada H et al. Role of diltiazem on tacrolimus pharmacokinetics in tacrolimus-induced nephrotoxic rats. 1999 Pharmacol. Toxicol. pmid:10401724
Katayama Y [Current tendency in treatment for acute ischemic stroke]. 1999 Nippon Ika Daigaku Zasshi pmid:10401232